Key facts
- This page summarizes Peter E. Boyd's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Mar 2022, 11:24.
Peter E. Boyd - 10 Mar 2022 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)
- Reporting relationship
- SVP-Bus. Process & Info. Tech.
- Issuer ticker
- AQST
- Reported as of
- 10 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2022, 11:24:48 UTC
- Next SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lori Braender, as Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter E. Boyd filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 14 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AQST
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +70,000
- Change %
- Price
- $0.000000
- Shares after
- 70,000
- Date
- 10 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,000
- Exercise price
- $2.55
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.